Neurocrine Biosciences, Inc. · NBIX · Next earnings

Neurocrine Biosciences, Inc. reports Wednesday, Feb 10, 2027

NBIX reports after market close with consensus EPS at $2.73 and revenue at $1.08B. Last quarter: Neurocrine Raises INGREZZA Outlook as Core Products Grow

Reports After market close99 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $2.73 Calendar consensus
Consensus revenue $1.08B Calendar consensus
Report date Feb 10, 2027 Wednesday, date estimated
Session After market close 99 days away

Where NBIX left off: FY2026 Q3

Full report

Neurocrine Raises INGREZZA Outlook as Core Products Grow

EPS surprise +72.3% Reported $3.29 vs $1.91
Revenue surprise +7.6% Reported $1.12B vs $1.04B
Stock move -0.5% Event window
Subsequent drift 0.0% Up to 20 sessions

Management raised full-year INGREZZA revenue guidance to $2.9 billion, from the prior quarter's $2.825–$2.875 billion range.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Mid- to high-single-digit net-price concessions expected for INGREZZA may pressure profitability.
  • VYKAT XR faces ongoing safety and regulatory scrutiny; management was asked about possible discontinuations and growth after launch-related bolus effects.
  • Commercial momentum depends on continued new-patient starts and persistency for VYKAT XR and continued adoption for CRENESITY.
  • Clinical efficacy, differentiation and eventual commercialization of pipeline programs remain uncertain.

Questions analysts left open

  • Why Q4 INGREZZA guidance implies a sequential decline and what headwinds are embedded in that outlook.
  • VYKAT XR's safety profile, possible regulatory engagement, discontinuation rates and sustainability of growth after the launch bolus.
  • The effect of pricing concessions on INGREZZA profitability.
  • How the company's CRF2 and GGG obesity programs may progress and differentiate.

Ask FN2 about NBIX next report

Transcript, numbers and history already loaded
What should I watch for in NBIX's next earnings report?How did NBIX guide last quarter, and is consensus above or below that?Give me the bull and bear case going into NBIX earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the NBIX recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent NBIX quarters

All NBIX earnings
-0.5%FY2026 Q3

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q3

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.